Meeting News

Fremanezumab may reduce frequency of migraine attack

Fremanezumab — a fully humanized monoclonal antibody targeting a calcitonin gene-related peptide that researchers said has already demonstrated efficacy for migraine prevention — could change some patients’ diagnosis from chronic to episodic migraine, according to findings presented at PainWeek.

“Patients with [chronic migraine] usually have more comorbid conditions and more- frequent medication overuse, which complicates their clinical management,” Joshua Cohen, MD, senior director, Global TA Lead Migraine and Headache at Teva Pharmaceuticals, and colleagues wrote.

Cohen led a 3-month trial that randomly assigned patients to receive either 675 mg of fremanezumab at baseline and then placebo at weeks 4 and 8; 675 mg of fremanezumab at baseline and 225 mg of fremanezumab at weeks 4 and 8; or only placebo during the entire 12-week period.

According to researchers, those who received fremanezumab went from having 15 or more headache days per month at baseline to fewer than 15 headache days per month for the duration of the study. In addition, the patients receiving fremanezumab had 18 to 19 headache days per month at baseline, numbers that dropped 6 to 9 days during any month in the treatment period. The results suggest patients’ diagnosis could shift from chronic migraine to episodic migraine, researchers wrote.

Man Holding Head
Fremanezumab — a fully humanized monoclonal antibody targeting a calcitonin gene-related peptide that researchers said has already demonstrated efficacy for migraine prevention — could change some patients’ diagnosis from chronic to episodic migraine, according to findings presented at PainWeek.

Photo Source:Adobe

Other findings involving similar doses of fremanezumab reported at PainWeek include:

  • efficacy in patients with chronic migraine who had used onabotulinumtoxinA or topiramate in the past; and
  • efficacy in preventive treatment of chronic migraine in patients with comorbid moderate to moderately severe depression, reducing migraine and headache frequency and improving depression.

Another study, in which patients with episodic migraine were randomly assigned to receive either 225 mg of fremanezumab every month for 1 year or 675 mg of fremanezumab every 3 months for 1 year, found that the efficacy and disability data seen at 1 month stayed constant during the study period. The same results occurred in a different study when similar doses of fremanezumab were tested in patients with chronic migraine, according to researchers. – by Janel Miller

References:

Brandes J, et al. Long-term Impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: Interim results of a one-year study.

Cohen J, et al. Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment.

Cohen J, et al. Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression.

McAllister P, et al. Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with chronic migraine: Interim results of a one-year study.

Yeung P, et al. Efficacy of fremanezumab in patients with chronic migraine who had prior use of topiramate or onabotulinumtoxinA.

Yeung P, et al. Impact of fremanezumab on the number of days with use of acute headache medications in chronic migraine.

All presented at: PainWeek 2018; Sept. 4-8, 2018; Las Vegas.

Disclosure: Healio Family Medicine was unable to determine relevant financial disclosures prior to publication.

Fremanezumab — a fully humanized monoclonal antibody targeting a calcitonin gene-related peptide that researchers said has already demonstrated efficacy for migraine prevention — could change some patients’ diagnosis from chronic to episodic migraine, according to findings presented at PainWeek.

“Patients with [chronic migraine] usually have more comorbid conditions and more- frequent medication overuse, which complicates their clinical management,” Joshua Cohen, MD, senior director, Global TA Lead Migraine and Headache at Teva Pharmaceuticals, and colleagues wrote.

Cohen led a 3-month trial that randomly assigned patients to receive either 675 mg of fremanezumab at baseline and then placebo at weeks 4 and 8; 675 mg of fremanezumab at baseline and 225 mg of fremanezumab at weeks 4 and 8; or only placebo during the entire 12-week period.

According to researchers, those who received fremanezumab went from having 15 or more headache days per month at baseline to fewer than 15 headache days per month for the duration of the study. In addition, the patients receiving fremanezumab had 18 to 19 headache days per month at baseline, numbers that dropped 6 to 9 days during any month in the treatment period. The results suggest patients’ diagnosis could shift from chronic migraine to episodic migraine, researchers wrote.

Man Holding Head
Fremanezumab — a fully humanized monoclonal antibody targeting a calcitonin gene-related peptide that researchers said has already demonstrated efficacy for migraine prevention — could change some patients’ diagnosis from chronic to episodic migraine, according to findings presented at PainWeek.

Photo Source:Adobe

Other findings involving similar doses of fremanezumab reported at PainWeek include:

  • efficacy in patients with chronic migraine who had used onabotulinumtoxinA or topiramate in the past; and
  • efficacy in preventive treatment of chronic migraine in patients with comorbid moderate to moderately severe depression, reducing migraine and headache frequency and improving depression.

Another study, in which patients with episodic migraine were randomly assigned to receive either 225 mg of fremanezumab every month for 1 year or 675 mg of fremanezumab every 3 months for 1 year, found that the efficacy and disability data seen at 1 month stayed constant during the study period. The same results occurred in a different study when similar doses of fremanezumab were tested in patients with chronic migraine, according to researchers. – by Janel Miller

References:

Brandes J, et al. Long-term Impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine: Interim results of a one-year study.

Cohen J, et al. Reversion of patients with chronic migraine to an episodic migraine classification with fremanezumab treatment.

Cohen J, et al. Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression.

PAGE BREAK

McAllister P, et al. Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with chronic migraine: Interim results of a one-year study.

Yeung P, et al. Efficacy of fremanezumab in patients with chronic migraine who had prior use of topiramate or onabotulinumtoxinA.

Yeung P, et al. Impact of fremanezumab on the number of days with use of acute headache medications in chronic migraine.

All presented at: PainWeek 2018; Sept. 4-8, 2018; Las Vegas.

Disclosure: Healio Family Medicine was unable to determine relevant financial disclosures prior to publication.

    See more from PAINWeek National Conference